环磷酰胺、硼替佐米与地塞米松诱导治疗新诊断多发性骨髓瘤患者的长期生存情况 - Suppr

Long-term survival with cyclophosphamide, bortezomib and dexamethasone induction therapy in patients with newly diagnosed multiple myeloma.

作者信息

Reeder Craig B, Reece Donna E, Kukreti Vishal, Mikhael Joseph R, Chen Christine, Trudel Suzanne, Laumann Kristina, Vohra Harjot, Fonseca Rafael, Bergsagel P Leif, Leis Jose F, Tiedemann Rodger, Stewart A Keith

机构信息

Hematology/Oncology, Mayo Clinic, Scottsdale, AZ, USA.

出版信息

Br J Haematol. 2014 Nov;167(4):563-5. doi: 10.1111/bjh.13004. Epub 2014 Jun 30.

DOI:10.1111/bjh.13004

PMID:24974945

Abstract

摘要

相似文献

Long-term survival with cyclophosphamide, bortezomib and dexamethasone induction therapy in patients with newly diagnosed multiple myeloma.环磷酰胺、硼替佐米与地塞米松诱导治疗新诊断多发性骨髓瘤患者的长期生存情况

Br J Haematol. 2014 Nov;167(4):563-5. doi: 10.1111/bjh.13004. Epub 2014 Jun 30.

Bortezomib subcutaneous injection in combination regimens for myeloma or systemic light-chain amyloidosis: a retrospective chart review of response rates and toxicity in newly diagnosed patients.硼替佐米皮下注射联合方案治疗多发性骨髓瘤或系统性轻链淀粉样变性：新诊断患者的反应率和毒性的回顾性图表分析。

Clin Ther. 2013 Oct;35(10):1614-20. doi: 10.1016/j.clinthera.2013.08.015. Epub 2013 Sep 26.

Once- versus twice-weekly bortezomib induction therapy with CyBorD in newly diagnosed multiple myeloma.在新诊断的多发性骨髓瘤中，硼替佐米与环磷酰胺、硼替佐米和地塞米松（CyBorD）联合使用时，每周一次与每周两次诱导治疗的对比

Blood. 2010 Apr 22;115(16):3416-7. doi: 10.1182/blood-2010-02-271676.

Phase 2 study of two sequential three-drug combinations containing bortezomib, cyclophosphamide and dexamethasone, followed by bortezomib, thalidomide and dexamethasone as frontline therapy for multiple myeloma.两阶段研究：两序贯三药联合方案包含硼替佐米、环磷酰胺和地塞米松，随后硼替佐米、沙利度胺和地塞米松作为多发性骨髓瘤的一线治疗。

Br J Haematol. 2010 Feb;148(4):562-8. doi: 10.1111/j.1365-2141.2009.07981.x. Epub 2009 Nov 16.

[Combination of bortezomib and dexamethasone for newly diagnosed multiple myeloma].硼替佐米与地塞米松联合用于新诊断的多发性骨髓瘤

Zhonghua Xue Ye Xue Za Zhi. 2009 Aug;30(8):543-7.

A comparison of bortezomib, cyclophosphamide, and dexamethasone (Vel-CD) chemotherapy without and with thalidomide (Vel-CTD) for the treatment of relapsed or refractory multiple myeloma.硼替佐米、环磷酰胺和地塞米松（Vel-CD）化疗与硼替佐米、环磷酰胺、地塞米松和沙利度胺（Vel-CTD）治疗复发或难治性多发性骨髓瘤的比较。

Ann Hematol. 2012 Jul;91(7):1023-30. doi: 10.1007/s00277-012-1420-7.

A new standard of care in newly diagnosed multiple myeloma.新诊断多发性骨髓瘤的一种新护理标准。

Lancet. 2010 Dec 18;376(9758):2043-4. doi: 10.1016/S0140-6736(10)62177-0. Epub 2010 Dec 9.

Randomized phase II study of bortezomib, thalidomide, and dexamethasone with or without cyclophosphamide as induction therapy in previously untreated multiple myeloma.硼替佐米、沙利度胺和地塞米松联合或不联合环磷酰胺作为诱导治疗方案治疗初治多发性骨髓瘤的随机 II 期研究。

J Clin Oncol. 2013 Jan 10;31(2):247-55. doi: 10.1200/JCO.2011.39.5137. Epub 2012 Oct 22.

[Effectiveness of bortezomib and bortezomib-containing programs for the treatment of recurrent and resistant multiple myeloma].硼替佐米及含硼替佐米方案治疗复发难治性多发性骨髓瘤的疗效

Ter Arkh. 2010;82(7):57-61.

Bortezomib dosing in relapsed multiple myeloma.复发多发性骨髓瘤中硼替佐米的给药剂量

Clin Lymphoma Myeloma. 2006 Sep;7(2):101-2. doi: 10.3816/CLM.2006.n.045.

引用本文的文献

Desmoplastic tumor priming using clinical-stage corticosteroid liposomes.使用临床阶段皮质类固醇脂质体进行促纤维增生性肿瘤启动。

Cell Biomater. 2025 Apr 22;1(3):None. doi: 10.1016/j.celbio.2025.100051.

Ixazomib, Oral Metronomic Cyclophosphamide, and Dexamethasone for First-Line Treatment of Multiple Myeloma: A Phase II Brown University Oncology Group Study.来那度胺、口服节拍式环磷酰胺和地塞米松作为一线治疗多发性骨髓瘤的方案：一项布朗大学肿瘤学组的 II 期研究。

Oncologist. 2023 May 8;28(5):462-e303. doi: 10.1093/oncolo/oyad017.

Bortezomib, epirubicin, and dexamethasone (PAD) results in superior free-progression survival compared to bortezomib, cyclophosphamide, and dexamethasone (VCD) treatment in non-transplantation newly diagnosed multiple myeloma patients aged between 50 to 65: a retrospective single-center analysis in non-transplant patients.与硼替佐米、环磷酰胺和地塞米松（VCD）治疗相比，硼替佐米、表柔比星和地塞米松（PAD）治疗可使年龄在50至65岁之间的非移植新诊断多发性骨髓瘤患者获得更长的无进展生存期：一项针对非移植患者的回顾性单中心分析。

Ann Transl Med. 2022 Jun;10(12):674. doi: 10.21037/atm-22-394.

Triplet RVd Induction for Transplant-Eligible Newly Diagnosed Multiple Myeloma: A Systematic Review and Meta-Analysis.三药 RVd 诱导方案治疗适合移植的初诊多发性骨髓瘤：系统评价和荟萃分析。

Adv Ther. 2022 Aug;39(8):3799-3834. doi: 10.1007/s12325-022-02195-1. Epub 2022 Jun 30.

Ixazomib with cyclophosphamide and dexamethasone in relapsed or refractory myeloma: MUKeight phase II randomised controlled trial results.来那度胺联合环磷酰胺和地塞米松治疗复发或难治性多发性骨髓瘤：MUKeight 期随机对照试验结果。

Blood Cancer J. 2022 Apr 1;12(4):52. doi: 10.1038/s41408-022-00626-4.

Genome Instability in Multiple Myeloma: Facts and Factors.多发性骨髓瘤中的基因组不稳定：事实与因素

Cancers (Basel). 2021 Nov 26;13(23):5949. doi: 10.3390/cancers13235949.

Proteasome Subunits Differentially Control Myeloma Cell Viability and Proteasome Inhibitor Sensitivity.蛋白酶体亚基差异控制骨髓瘤细胞活力和蛋白酶体抑制剂敏感性。

Mol Cancer Res. 2020 Oct;18(10):1453-1464. doi: 10.1158/1541-7786.MCR-19-1026. Epub 2020 Jun 19.

Reduced Weekly Subcutaneous Doses of Bortezomib in Combination with Cyclophosphamide and Dexamethasone for Newly Diagnosed Multiple Myeloma.硼替佐米与环磷酰胺和地塞米松联合使用时每周皮下给药剂量减少用于新诊断的多发性骨髓瘤

J Res Pharm Pract. 2020 Mar 28;9(1):56-59. doi: 10.4103/jrpp.JRPP_18_82. eCollection 2020 Jan-Mar.

Synergistic Efficacy of the Demethylation Agent Decitabine in Combination With the Protease Inhibitor Bortezomib for Treating Multiple Myeloma Through the Wnt/β-Catenin Pathway.地西他滨联合蛋白酶体抑制剂硼替佐米通过 Wnt/β-连环蛋白通路治疗多发性骨髓瘤的协同疗效。

Oncol Res. 2019 Jun 21;27(6):729-737. doi: 10.3727/096504018X15443011011637. Epub 2019 Mar 5.

Daratumumab, bortezomib, cyclophosphamide and dexamethasone in newly diagnosed and relapsed multiple myeloma: LYRA study.达雷妥尤单抗、硼替佐米、环磷酰胺和地塞米松治疗新诊断和复发多发性骨髓瘤的 LYRA 研究。

Br J Haematol. 2019 May;185(3):492-502. doi: 10.1111/bjh.15806. Epub 2019 Mar 3.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Long-term survival with cyclophosphamide, bortezomib and dexamethasone induction therapy in patients with newly diagnosed multiple myeloma.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

文献检索

文件翻译

深度研究

Suppr 超能文献

相似文献

引用本文的文献